Highest-materiality recent filing
Plus Therapeutics enters into $17.35M ATM equity distribution agreement with Canaccord Genuity
Up to $17.35M of common stock may be sold at-the-market through Canaccord Genuity as agent.
Plus Therapeutics holds annual meeting post 1-for-25 reverse split; all proposals pass
All six directors elected; votes for ranged from 11.9M to 12.4M; broker non-votes ~50.8M.
Plus Therapeutics Q1 net loss $6.9M; REYOBIQ gets FDA Orphan Drug Designation
Cash and investments $15.1M as of March 31, 2026, up from $8.6M at Dec 2025 after $15M public offering.
Plus Therapeutics regains Nasdaq minimum bid price compliance after 1-for-25 reverse split
Nasdaq notified Plus Therapeutics on April 20, 2026 that bid price closed at or above $1.00 for 10 consecutive days through April 17.
Plus Therapeutics appoints Eric J. Daniels as CDO; base salary $460K, equity grant
Daniels becomes Chief Development Officer effective April 20, 2026, reporting to CEO.
Plus Therapeutics' REYOBIQ gets FDA Orphan Drug Designation for pediatric malignant gliomas
ODD covers pediatric malignant gliomas including ependymoma, broader than originally requested.
Plus Therapeutics approves 1-for-25 reverse stock split to meet Nasdaq $1.00 minimum bid price
Reverse split at 1-for-25, effective 12:01 a.m. ET on April 2, 2026; shares drop from ~171.6M to ~6.86M.
Plus Therapeutics appoints Ronald A. Andrews to board; Robert Lenk resigns
Robert Lenk resigned as director and Nominating Committee member effective March 20, 2026; no policy disagreement cited.
Net loss $22.4M ($0.29/shr) vs $13.0M ($1.95/shr) in 2024; operating loss $15.3M vs $14.7M.
Plus Therapeutics sets 2026 annual meeting for May 14; proxy deadlines March 22
Annual meeting scheduled for May 14, 2026 at 9:00 a.m. ET, held virtually.
Plus Therapeutics Approves FY2025 Cash Bonuses: CEO Hedrick Gets $305,663, CFO Sims Gets $149,175
On Feb 9, 2026, Compensation Committee approved discretionary cash bonuses for Named Executive Officers for FY2025.
Plus Therapeutics updates corporate presentation; no specific new data disclosed
Filed updated investor presentation under Item 8.01.
Plus Therapeutics prices $15M public offering of 39.5M units at $0.38; net ~$13.3M
Offering of 39,473,684 units at $0.38 each, each unit = one share + one warrant.
Plus Therapeutics gets Nasdaq extension until May 11, 2026 to regain $1 bid price
Received 180-day extension to May 11, 2026 from Nasdaq to meet $1.00 minimum bid price rule.
Plus Therapeutics Q3 net loss $0.04/shr; cash $16.6M; CNSide commercial launch advances
Net loss of $4.4M ($0.04/shr) vs $2.9M ($0.37/shr) in Q3 2024; operating loss $4.5M.
Lease covers 11,370 rentable square feet on third floor of 6420 Levit Green Blvd, Houston; 120-month term.
Nasdaq confirmed compliance with MVLS ($35M) and equity ($2.5M) standards on Aug 22, 2025.
Plus Therapeutics Q2 2025: net income $5.2M on derivative gain; CNSide assay launched in Texas
Cash $6.9M at June 30, 2025 vs $3.6M at Dec 31, 2024; operating loss $1.5M vs $3.7M in Q2 2024.
Plus Therapeutics Regains Nasdaq Compliance; Reports $3M Stockholders' Equity and $35M+ MVLS
Reported stockholders' equity of $3M as of June 30, 2025, satisfying Nasdaq's minimum $2.5M Equity Rule.
Plus Therapeutics updates Nasdaq listing; panel grants continued listing with conditions
Nasdaq panel granted continued listing; must demonstrate $2.5M stockholders' equity compliance by Aug 14, 2025.
All six director nominees were elected to the board for a term expiring at the 2026 annual meeting.
Plus Therapeutics dismisses BDO, engages CBIZ as new auditor; prior reports note going concern
Audit committee dismissed BDO USA, P.C. as independent auditor on July 16, 2025.
Plus Therapeutics enters $50M common stock purchase agreement with Lincoln Park Capital
Plus Therapeutics signed a purchase agreement with Lincoln Park Capital for up to $50 million of common stock over 36 months.
Plus Therapeutics cuts Series B warrant shares from 1.26B to 35.5M; cancels Series A warrants
Cancelled all Series A warrants exercisable for up to 280M shares of common stock.
Plus Therapeutics gets Nasdaq delisting notice for negative stockholders' equity
Company reported stockholders' equity deficit of $23.6M as of March 31, 2025, failing Nasdaq's $2.5M minimum.
Plus Therapeutics Q1 net loss $17.4M; cash jumps to $9.9M on $15M financing and grants
Cash balance $9.9M at Mar 31, 2025 vs $0.1M at Dec 31, 2024; raised $15M private placement and $2M grant advance.
Plus Therapeutics receives Nasdaq deficiency notice for late Q1 10-Q filing
Received Nasdaq notice on May 21, 2025 for missing Q1 2025 Form 10-Q filing deadline.
Plus Therapeutics receives Nasdaq delisting notice for bid price below $1.00
Nasdaq notified Plus Therapeutics on May 16, 2025 of non-compliance with minimum bid price rule (closing bid < $1.00 for 30 consecutive days).
Authorized common shares increased from 100M to 2B; reverse split authorized at ratio between 1:25 and 1:250.
Plus Therapeutics appoints Kyle Guse to board; Greg Petersen resigns
Kyle Guse appointed to board effective April 18, 2025, filling vacancy from Greg Petersen's resignation.
Plus Therapeutics reports 2024 net loss of $13.0M, cash $3.6M; raised $15M in private placement
Cash and investments $3.6M at Dec 31, 2024 vs $8.6M at Dec 31, 2023.
Plus Therapeutics regains Nasdaq minimum equity compliance after private placement
Received Nasdaq letter dated March 7, 2025 confirming compliance with minimum stockholders' equity requirement (Rule 5550(b)(1)).
Plus Therapeutics raises $15M in private placement; exchanges $3.2M in convertible notes
Private placement of ~28M shares (or prefunded warrants) at $0.66/unit, each with Series A and B warrants.
Issued $3.36M in secured convertible notes and warrants to purchase ~3M shares at $1.12; aggregate proceeds ~$3.7M.
Plus Therapeutics Q3 net loss $9.1M, cash $4.8M; FDA clears Phase 1 LM trial
Net loss YTD Sep 30, 2024: $9.1M ($1.46 basic EPS) vs $9.5M ($3.54) prior year; operating loss $10.8M vs $9.5M.
Plus Therapeutics receives Nasdaq extension until March 4, 2025 to regain minimum equity compliance
Nasdaq Hearings Panel granted extension to March 4, 2025 for Plus Therapeutics to meet $2.5M stockholders' equity minimum.
Plus Therapeutics receives Nasdaq delisting notice; plans appeal to stay listing
Nasdaq notified on Sept 5, 2024 that company failed to regain compliance with minimum $2.5M stockholders' equity rule.
All six director nominees elected: Clowes, van Es-Johansson, Hawkins, Hedrick, Lenk, Petersen. Votes For ranged 1.16M-1.18M.
Plus Therapeutics Q2 2024: ReSPECT-LM Phase 1 shows median OS 12 months; net loss $6.2M
ReSPECT-LM Phase 1 safe in 16 patients; median overall survival 12 months, 8 of 16 alive.
Plus Therapeutics CMO Dr. Norman LaFrance resigns effective June 12, 2024
Dr. Norman LaFrance resigned as Chief Medical Officer on June 5, 2024.
Plus Therapeutics draws $3.3M from Pershing facility to repay Oxford term loan in full
Drew $3.3M from Pershing margin loan facility at FOMC target (floor 5.5%) + 1.75% spread + 0.5% fees, max Prime+3%.
Plus Therapeutics sets 2024 annual meeting for August 15; stockholder proposals due May 30
Annual meeting to be held virtually on August 15, 2024 at 9:00 a.m. Eastern Time.
Plus Therapeutics Q1 2024 net loss $3.3M; cash $3M; secures up to $19.25M financing
Net loss of $3.3M ($0.75 per share) vs $4.8M ($2.07) in Q1 2023; grant revenue rose to $1.7M from $0.5M.
PSTV raises $7.25M via private placement of shares and warrants
Gross proceeds of $7.25M from private placement of 3,591,532 units at $2.022/$2.158 per unit.
Plus Therapeutics receives Nasdaq delisting notice for equity deficiency
Stockholders' equity was ($1,348,000) as of Dec 31, 2023, below Nasdaq's $2.5M minimum.
Plus Therapeutics CEO presents at JonesResearch webcast; no material new details in filing
CEO Marc Hedrick presented at a JonesResearch webcast on March 12, 2024.
Plus Therapeutics reports FY2023 net loss $13.3M; cash $8.6M; ReSPECT-LM advances to Cohort 5
Net loss $(13.3)M ($4.24 per share) vs $(20.3)M ($11.58 per share) in 2022; operating loss improved to $13.3M from $19.7M.
Plus Therapeutics Phase 2 GBM trial: mOS 13 mo (63% above SOC), mPFS 11 mo
Median overall survival 13 months in 15 rGBM patients, 63% better than SOC bevacizumab (8 mo).
Plus Therapeutics Q3 net loss $3.2M ($1.00/share); cash $11M, runway into 2025
Net loss $3.2M ($1.00 per share) vs $5.2M ($2.85) in Q3 2022; operating expenses $4.5M.
Plus Therapeutics board authorizes $500K share repurchase program
Board approved repurchase of up to $500,000 of common stock over 12 months.
On April 18, 2025, Mr. Greg Petersen resigned as a member of the Board. Mr. Petersen informed the Company that his resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
On April 18, 2025, the Board of Directors (the “Board”) of Plus Therapeutics, Inc (the “Company”) unanimously appointed Mr. Kyle Guse to serve as a director of the Board, effective immediately.
On June 5, 2024, Plus Therapeutics, Inc. (the “Company”) received the resignation of Dr. Norman LaFrance, its Chief Medical Officer.
On September 13, 2021, Plus Therapeutics, Inc. (the “Company”) announced the appointment of Dr. Norman LaFrance as Chief Medical Officer (“CMO”) and Senior Vice President of the Company, effective on or around December 8, 2021.
Max materiality 0.95 · Median 0.65 · Most common event other_material